FINEVINE LLC – Trademark Portfolio
Entity Type: 16
FINEVINE LLC holds 13 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 3 (Cosmetics & Cleaning) — 8 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 4 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include HEMOX, DAILY REMEDY, and SELF CARE YOU CAN BELIEVE IN. The owner is based in HAMILTON, NJ.
3817 CROSSWICKS HAMILTON SQUARE ROAD
SUITE 148
HAMILTON, NJ 08691
Showing of trademarks Trademarks
Trademark Classifications
FINEVINE LLC's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Apparatus for lighting, heating, steam generating, cooking, refrigerating, drying
Frequently Asked Questions
How many trademarks does FINEVINE LLC have?
FINEVINE LLC has 13 U.S. trademarks filed with the USPTO. Of these, 5 registered, 1 abandoned, 7 cancelled.
What trademark classes does FINEVINE LLC file in?
FINEVINE LLC files trademarks across 4 Nice Classification classes. The most active classes are Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals), Class 11 (Environmental Control), Class 8 (Hand Tools). Class 3 covers bleaching preparations and other substances for laundry use; cleaning, polishing, scouring.
What are FINEVINE LLC's most well-known trademarks?
FINEVINE LLC's registered trademark portfolio includes well-known marks such as HEMOX, DAILY REMEDY, and SELF CARE YOU CAN BELIEVE IN. These are among 5 currently registered trademarks in the portfolio.
What is FINEVINE LLC's trademark registration success rate?
FINEVINE LLC has a 38% trademark registration rate, with 5 out of 13 resolved applications resulting in successful registration. Currently, 0 applications are pending review.